Cart
sales@molnova.com
Cbl-b-IN-5
CAS No. 2368835-59-8
Cbl-b-IN-5( —— )
Catalog No. M36958 CAS No. 2368835-59-8
Cbl-b-IN-5 is a potent CPL-B inhibitor with IC50 values between 3 and 10 μM. Cbl-b-IN-5 has been used to study cancer and diseases related to the immune system.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 178 | In Stock |
|
| 10MG | 278 | In Stock |
|
| 25MG | 566 | In Stock |
|
| 50MG | 1014 | In Stock |
|
| 100MG | 1451 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 2911 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCbl-b-IN-5
-
NoteResearch use only, not for human use.
-
Brief DescriptionCbl-b-IN-5 is a potent CPL-B inhibitor with IC50 values between 3 and 10 μM. Cbl-b-IN-5 has been used to study cancer and diseases related to the immune system.
-
DescriptionCbl-b-IN-5 (compound 6) is a Cbl-b inhibitor (IC50=3-10 μM). Cbl-b-IN-5 has the potential to be used in the study of cancer and related diseases amenable to immune system modulation.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2368835-59-8
-
Formula Weight339.42
-
Molecular FormulaC17H17N5OS
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (294.63 mM; Ultrasonic )
-
SMILESO=C(NC1=CC=CC(=C1)C(SC2=NN=CN2C)C)C3=NC=CC=C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Paul A. Barsanti, et al. Inhibitors of cbl-b and methods of use thereof. Patent WO2019148005A1.
molnova catalog
related products
-
DB772
DB772 is a broad-spectrum antiviral activity that inhibits Bovine Viral Diarrhea Virus (BVDV), prion activity, Border Disease Virus (BDV), HoBi Virus, Forked Horn Virus and Bungowannah Virus.
-
[Tyr4] - MBP (1 - 11...
[Tyr4] - MBP (1 - 11)
-
Divalproex Sodium
Divalproex Sodium binds to and inhibits gamma-aminobutyric acid (GABA) transaminase and its anticonvulsant activity may be exerted by increasing brain concentration of GABA and by inhibiting enzymes that catabolize GABA or block the reuptake of GABA into glia and nerve endings.
